← Browse by Condition
Medical Condition

myelodysplastic syndromes

Total Trials
27
Recruiting Now
27
Trial Phases
Phase 2, EARLY_Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for myelodysplastic syndromes sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myelodysplastic syndromes Clinical Trials

How many clinical trials are currently recruiting for myelodysplastic syndromes?
ClinicalMetric currently tracks 27 actively recruiting clinical trials for myelodysplastic syndromes, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 27. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for myelodysplastic syndromes?
myelodysplastic syndromes research spans Phase 1 (10 trials), Phase 2 (12 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a myelodysplastic syndromes clinical trial?
Eligibility criteria for myelodysplastic syndromes trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
10
Phase 2
12
Top Sponsors
Children's Hospital of Philadelphia 2 trials
Dana-Farber Cancer Institute 2 trials
Masonic Cancer Center, University of Minnesota 2 trials
Takeda 1 trial
St. Jude Children's Research Hospital 1 trial

Recruiting Clinical Trials

NCT04419649 Phase 2
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Enrollment
160 pts
Location
United States, Austr...
Sponsor
Takeda
View Trial →
NCT03810196
Recruiting
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Enrollment
50 pts
Location
United States
Sponsor
Children's Hospital of Philade...
View Trial →
NCT02720679
Recruiting
Investigation of the Genetics of Hematologic Diseases
Enrollment
1,716 pts
Location
United States
Sponsor
St. Jude Children's Research H...
View Trial →
NCT04187703 EARLY_Phase 1
Recruiting
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Enrollment
20 pts
Location
United States
Sponsor
Benjamin Tomlinson
View Trial →
NCT03016806
Recruiting
Umbilical Cord Blood Transplantation From Unrelated Donors
Enrollment
30 pts
Location
United States
Sponsor
University of Rochester
View Trial →
NCT06508099 Phase 2
Recruiting
Vitamin A and D Supplementation in Allogeneic HCT
Enrollment
220 pts
Location
Russia
Sponsor
St. Petersburg State Pavlov Me...
View Trial →
NCT02269592
Recruiting
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Enrollment
10,000 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT06270771
Recruiting
OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study
Enrollment
60 pts
Location
Canada
Sponsor
Sunnybrook Health Sciences Cen...
View Trial →
NCT03579875 Phase 2
Recruiting
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Enrollment
48 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
View Trial →
NCT04581512 Phase 1, Phase 2
Recruiting
Study to Evaluate the Safety and Tolerability of EP0042
Enrollment
70 pts
Location
Australia, Netherlan...
Sponsor
Ellipses Pharma
View Trial →
NCT05194397 Phase 2
Recruiting
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Enrollment
80 pts
Location
United States
Sponsor
Children's Hospital of Philade...
View Trial →
NCT04024761 Phase 1
Recruiting
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Enrollment
50 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT06047886 Phase 1
Recruiting
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Enrollment
50 pts
Location
United States
Sponsor
University of Alabama at Birmi...
View Trial →
NCT06918834 Phase 2
Recruiting
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Enrollment
236 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT07216443 Phase 2
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment
80 pts
Location
United States
Sponsor
Orca Biosystems, Inc.
View Trial →
NCT06802315 Phase 2
Recruiting
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
Enrollment
38 pts
Location
United States
Sponsor
University of Illinois at Chic...
View Trial →
NCT06303193 Phase 1, Phase 2
Recruiting
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Enrollment
160 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT07270978 Phase 1
Recruiting
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Enrollment
23 pts
Location
United States
Sponsor
University of Virginia
View Trial →
NCT04245397 Phase 1
Recruiting
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Enrollment
151 pts
Location
United States
Sponsor
Syntrix Biosystems, Inc.
View Trial →
NCT02074839 Phase 1
Recruiting
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Enrollment
291 pts
Location
United States, Franc...
Sponsor
Institut de Recherches Interna...
View Trial →
NCT04935684 Phase 2
Recruiting
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Enrollment
150 pts
Location
France
Sponsor
University Hospital, Clermont-...
View Trial →
NCT03533816 Phase 1
Recruiting
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Enrollment
38 pts
Location
United States
Sponsor
University of Kansas Medical C...
View Trial →
NCT01137643
Recruiting
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Enrollment
15,000 pts
Location
United States
Sponsor
UNC Lineberger Comprehensive C...
View Trial →
NCT05805605 Phase 2
Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
Enrollment
56 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
View Trial →
NCT07566377 Phase 2
Recruiting
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Enrollment
71 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT03964506 EARLY_Phase 1
Recruiting
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Enrollment
24 pts
Location
United States
Sponsor
Omar Aljitawi
View Trial →
NCT07183878
Recruiting
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
Enrollment
138 pts
Location
China
Sponsor
First Affiliated Hospital of Z...
View Trial →

Related Conditions

acute myeloid leukemia (8) acute lymphoblastic leukemia (4) lymphoma (3) acute leukemia (2) lymphoblastic lymphoma (2) burkitt lymphoma (2) juvenile myelomonocytic leukemia (2) dyskeratosis congenita (2) fanconi anemia (2) aplastic anemia (2) biphenotypic acute leukemia (2) chronic myeloid leukemia (2)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology